• Select your country/language
  • United States
  • Argentina
  • Australia
  • Belgique (Belgium) - Français
  • België (Belgium) – Nederlands
  • Brasil (Brazil)
  • Canada – English
  • Canada – French
  • Chile
  • Colombia
  • Danmark (Denmark)
  • Deutschland (Germany)
  • España (Spain)
  • France – Français
  • Israel
  • Italia (Italy)
  • Japan - 日本
  • Magyarország (Hungary)
  • México
  • Nederland (Netherlands)
  • New Zealand
  • Norge (Norway)
  • Panamá
  • Perú
  • Poland
  • Portugal
  • Puerto Rico
  • Schweiz (Switzerland) - Deutsch
  • South Africa
  • Suisse (Switzerland) – Français
  • Suomi (Finland)
  • Sverige (Sweden)
  • Svizzera (Switzerland) – Italiano
  • Türkiye (Turkey)
  • United Kingdom
  • Österreich (Austria)
  • Česká republika (Czech Republic)
  • Ελλάδα (Greece)
Medtronic logo
placeUnited States
Contact Us
  • Covidien Products
  • Clinical Solutions
  • Clinical Education
  • Support
  • placeUnited States
Cancel
Medtronic / Clinical Solutions / Ventilator-Associated Pneumonia / Outcomes

Ventilator-Associated Pneumonia
  • Incidence
  • Outcomes
  • Pathogenesis
  • Interventions
  • Guidelines

Outcomes

VAP is associated with increased mortality, length of stay and costs.

Mortality Rates in Patients with VAP Versus Controls

Back

Mortality Rates in Patients with VAP Versus Controls
  VAP Mortality Control Mortality Difference
Bercault 2001([FOOTNOTE=Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med. 2001;29(12):2303-2309. ],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=805224]) 
(p< 0.0001)
41.00% 14.00% 27.00%
Warren 2003([FOOTNOTE=Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med. 2003;31(5):1312-1317.],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=277904])
(p< 0.001)
50.00% 34.00% 16.00%
Rello 2002([FOOTNOTE=Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002;122(6):2115-2121.],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=805225]) 
(p< 0.713)
30.50% 30.40% 0.10%
Ibrahim 2001([FOOTNOTE=Ibrahim EH, Tracy L, Hill C, Fraser VJ, Kollef MH. The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes. Chest. 2001;120(2):555-561. ],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=805222]) 
(p< 0.004)
45.50% 32.20% 13.30%
Kollef 2005([FOOTNOTE=Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128(6):3854-3862.],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=805226]) 
(p< 0.0001)
29.30% 10.00% 19.30%

VAP - Attributable Mortality at 30 and 60 Days

Back

VAP - Attributable Mortality at 30 and 60 Days
  Attributable Mortality
Bekaert 2011([FOOTNOTE=Bekaert M, Timsit JF, Vansteelandt S, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 2011;184(10):1133-1139. ],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=476875]) 
(30 Day)
4.40%
Bekaert 20116 
(60 Day)
5.90%

Hospital Length of Stay (LOS) May Increase in Patients with VAP Versus Controls

Back

Hospital Length of Stay (LOS) May Increase in Patients with VAP Versus Controls
  VAP Hospital LOS Control Hospital LOS Difference
Warren 20032
(p< 0.001)
38 13 25
Rello 20023
(p< 0.001)
25.5 14 11.5
Kollef 20055
(p< 0.0001)
23 7.5 15.5

ICU Length of Stay (LOS) May Increase in Patients with VAP Versus Controls

Back

ICU Length of Stay (LOS) May Increase in Patients with VAP Versus Controls
  VAP ICU LOS Control ICU LOS Difference
Bercault 20011
(p< 0.0001)
31 26 5
Warren 20032
(p< 0.001)
26 4 22
Rello 20023
(p< 0.001)
11.7 5.6 6.1

Hospital Costs May Increase in Patients with VAP Versus Controls

Back

Hospital Costs May Increase in Patients with VAP Versus Controls
  VAP Costs Control Costs Difference
Warren 20032
(p< 0.001)
$70,568 $21,620
$48,948
Rello 20023 
(p< 0.001)
$104,983 $63,689 $41,294
Kollef 20055 
(p< 0.0001)

$150,841 $25,218 $125,623
Hugonnet 2004([FOOTNOTE=Hugonnet S, Eggimann P, Borst F, Maricot P, Chevrolet JC, Pittet D. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol. 2004;25(12):1090-1096.],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=277906]) 
(p< 0.001)
$24,727 $17,438 $7,289
Corporate Resources
  • Medtronic.com
  • Terms of Use
  • Privacy Statement
  • Suppliers
  • Digital Millennium Copyright Act (DMCA) Notification
  • Proposition 65 Information for California Customers
  • External Research Program
  • News
Medical Surgical Portfolio
  • Covidien Products
  • Clinical Solutions
  • Clinical Education
  • Support
  • Events
  • Blog
  • Email Preferences
  • Sitemap
Patient Resources
  • Barrett's Esophagus
  • Breath Monitoring
  • Colon Diseases
  • Hernia Treatment
  • Homecare Ventilation & Tracheostomy
  • Lung Cancer
  • Weight Loss & Obesity
Additional Resources
  • Educational Grants
  • Animal Health
Contact Us
Operational Headquarters

710 Medtronic Parkway

Minneapolis, MN

55432-5604

USA

©2023 Medtronic